Patent 9023357 was granted and assigned to Bayer Healthcare on May, 2015 by the United States Patent and Trademark Office.
Provided are a wide concentration range, especially high concentration anti-prolactin receptor antibody formulations that are substantially isosmotic and of low viscosity.